Effects of partnership change on microbicide gel adherence in a clinical trial (HPTN 035)
- PMID: 24158488
- PMCID: PMC3988261
- DOI: 10.1007/s10461-013-0651-5
Effects of partnership change on microbicide gel adherence in a clinical trial (HPTN 035)
Abstract
Use of HIV prevention methods may vary for women by types of sexual partners. In a microbicide safety and effectiveness trial (HPTN 035) differences in adherence to a microbicide study gel were compared between women with new versus ongoing partnerships over time. 1,757 women in the three HPTN 035 trial's arms completed the Follow-up Partner Status (FPS) questionnaire at their last study visit. Women married at baseline were asked if they had the same husband, new husband or new partner. Unmarried women were asked if they had changed partners or married. Self-reported gel adherence during the last sex act was compared at each quarterly visit between women with ongoing versus new partners. High gel adherence was compared with low gel adherence (85-100 vs. <85 % of last vaginal sex acts reported with gel use, respectively) in multivariable models to assess associations with partner change. Overall 7 % of women (n = 123) reported a new partner and 41 % (51) of those reported a new husband. Median gel adherence was reported to be 100 % in women with ongoing partners and 75 % for women with new partners (p < 0.001). In women reporting no gel use in their last sex act, only 12.5 % of the women with a new partner and none of those with an ongoing partner reported using condoms (p < 0.001). Fewer women with new partners reported using both the gel and condom during the last sex act as compared to women with ongoing partners (median 50 vs. 71.4 %, p < 0.001). After adjusting for age, site, education level, and sexual frequency, women with ongoing partners were more likely to report high gel adherence than those with new partners (AOR 2.5, 95 % CI 1.6, 3.9). This pattern persisted when gel use over time was compared between women with new versus ongoing partners. In the HPTN 035 trial, women with new partners had higher HIV incidence and reported less gel use and higher condom use. Specific counseling and support are needed to help women use potential HIV prevention methods, including microbicides, when they are changing partners.
Figures
Similar articles
-
Prevention, Partners, and Power Imbalances: Women's Views on How Male Partners Affected Their Adherence to Vaginal Microbicide Gels During HIV Prevention Trials in Africa.J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):458-465. doi: 10.1097/QAI.0000000000002463. J Acquir Immune Defic Syndr. 2020. PMID: 33136745 Free PMC article.
-
Hidden heterogeneity: Uncovering patterns of adherence in microbicide trials for HIV prevention.PLoS One. 2022 May 12;17(5):e0267011. doi: 10.1371/journal.pone.0267011. eCollection 2022. PLoS One. 2022. PMID: 35551324 Free PMC article.
-
Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda.Trials. 2013 Feb 1;14:33. doi: 10.1186/1745-6215-14-33. Trials. 2013. PMID: 23374729 Free PMC article. Clinical Trial.
-
Shifts in condom use following microbicide introduction: should we be concerned?AIDS. 2003 May 23;17(8):1227-37. doi: 10.1097/00002030-200305230-00015. AIDS. 2003. PMID: 12819525 Review.
-
Microbicide clinical trial adherence: insights for introduction.J Int AIDS Soc. 2013 Apr 8;16(1):18505. doi: 10.7448/IAS.16.1.18505. J Int AIDS Soc. 2013. PMID: 23561044 Free PMC article. Review.
Cited by
-
How Do We Get Partners to Test for HIV?: Predictors of Uptake of Partner HIV Testing Following Individual Outpatient Provider Initiated HIV Testing in Rural Uganda.AIDS Behav. 2017 Aug;21(8):2497-2508. doi: 10.1007/s10461-017-1817-3. AIDS Behav. 2017. PMID: 28585100 Free PMC article.
-
Prevention, Partners, and Power Imbalances: Women's Views on How Male Partners Affected Their Adherence to Vaginal Microbicide Gels During HIV Prevention Trials in Africa.J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):458-465. doi: 10.1097/QAI.0000000000002463. J Acquir Immune Defic Syndr. 2020. PMID: 33136745 Free PMC article.
-
Acceptability of a Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-033 Study).AIDS Educ Prev. 2021 Oct;33(5):361-376. doi: 10.1521/aeap.2021.33.5.361. AIDS Educ Prev. 2021. PMID: 34596427 Free PMC article.
-
The promise and peril of pre-exposure prophylaxis (PrEP): using social science to inform prep interventions among female sex workers.Afr J Reprod Health. 2014 Sep;18(3 Spec No):74-83. Afr J Reprod Health. 2014. PMID: 26050379 Free PMC article. Review.
-
Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial.AIDS Behav. 2013 Mar;17(3):1002-15. doi: 10.1007/s10461-012-0358-z. AIDS Behav. 2013. PMID: 23114512 Free PMC article. Clinical Trial.
References
-
- Karim QA, Baxter C, Karim SA. Topical microbicides--what’s new? Journal of acquired immune deficiency syndromes. 2013 Jul;63(Suppl 2):S144–149. - PubMed
-
- Baeten J, Donnell D, Ndase P, et al. ARV PrEP for HIV-1 Prevention among Heterosexual Men and Women; 19th Conference on Retroviruses and Opportunistic Infections (CROI); Seattle. 2012.
-
- Van Damme L, Corneli A, Ahmed K, et al. The FEM-PrEP Trial of Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) among African Women; Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI); Seattle. Mar 5–8, 2012. 2012.
-
- Montgomery CM, Lees S, Stadler J, et al. The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care. 2008;20(6):733–740. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous